Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.

First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.

Sidharth Ghosh is an IT professional, sportsman and kidney cancer survivor in Delhi, India.

Two years later, Michael Mullan’s cancer is still at bay because of immunotherapy and targeted chemotherapy.

Dual checkpoint inhibitors improve response rate and survival for people with intermediate or poor risk.

Immunotherapy combo was more effective and better tolerated for first-time treatment.

Are immunotherapy and targeted therapies ready to replace toxic chemotherapy?

The FDA previously approved Cabometyx in 2016 for treatment of patients with advanced RCC who have received prior anti-angiogenic therapy.

FDA approves sunitinib malate (Sutent) for the adjuvant treatment of adults at risk for kidney cancer recurrence.